Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLUTO
2023-509450-55-01Phase 2Authorised
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Type 1 diabetes mellitus with chronic kidney disease comparing sotagliflozin with placebo (2 arms). Primary endpoint: Change in renal blood oxygenation (BOLD MRI R2* signal). Planned start Aug 2024; status: authorised.
02
Drugs
sotagliflozin
03
Conditions
Type 1 diabetes mellitus with chronic kidney disease
Beyond the preview
Go deeper on 2023-509450-55-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509450-55-01.